GHRP-2
Growth Hormone Releasing Peptide-2
GHRP-2 (Pralmorelin) is a synthetic hexapeptide that acts as a potent GH secretagogue via GHSR-1a activation. It was among the first GHRPs to enter clinical trials and is one of the most extensively studied in this class. It produces stronger GH pulses than Ipamorelin but with moderate cortisol and prolactin elevation at higher doses.
Mechanism of Action
GHRP-2 activates the ghrelin receptor (GHSR-1a) in the pituitary and hypothalamus. Hypothalamic activation leads to reduced somatostatin tone (the GH release inhibitor), while pituitary activation directly triggers GH secretion. This dual-site action partially explains its potency advantage over single-site GHRPs.
At research doses (100–300 mcg), cortisol and prolactin elevations are modest and transient. At higher doses (>500 mcg), significant cortisol elevation is observed via ACTH co-stimulation — a key reason Ipamorelin is often preferred for chronic protocols.
Research Evidence
GHRP-2 has been extensively studied in humans including as a diagnostic tool for GH deficiency assessment. Its well-characterised dose-response relationship makes it a reference compound in the GHRP class.
GHRP-2 as a Diagnostic Test for Growth Hormone Deficiency
GHRP-2 combined with GHRH demonstrated superior diagnostic sensitivity for adult GH deficiency compared to insulin tolerance testing, with fewer adverse effects — supporting its utility as a pituitary stimulation test.
Typical Research Protocol
Often combined with CJC-1295. Higher doses (>300 mcg) are not recommended due to cortisol/prolactin co-stimulation. GHRP-2 + GHRH produces GH responses 3–5× larger than GHRP-2 alone.
Safety Profile
Reported Side Effects
- Cortisol elevation (dose-dependent)
- Prolactin increase (transient)
- Increased appetite
- Water retention
- Tingling
- Injection site redness
Contraindications
- Active malignancy
- Hypothyroidism
- Pregnancy
- Inflammatory conditions (cortisol risk)
Published Research
212 indexed PubMed papers reference GHRP-2. The 20 most recent are listed below.
- Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests.
- The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.
- Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone.
- Diurnal and Daily Variations in Growth Hormone and Growth Hormone Stimulation Test in Male Cynomolgus Monkeys.
- One Case of Sudden Isolated Adrenocorticotropic Hormone (ACTH) Deficiency Diagnosed Based on Repeated Hypoglycemic Attacks.
- Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism.
- Growth Hormone-Releasing Peptide 2 May Be Associated With Decreased M1 Macrophage Production and Increased Histologic and Biomechanical Tendon-Bone Healing Properties in a Rat Rotator Cuff Tear Model.
- Assessment of anterior pituitary reserve capacity based on growth hormone response to growth hormone-releasing peptide-2 test in the elderly.
- Pharmacotherapy in Cachexia: A Review of Endocrine Abnormalities and Steroid Pharmacotherapy.
- Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.
- Refractory hypoglycaemia in a localised gastrointestinal stromal tumour: Case report.
- On the road of dried blood spot sampling for antidoping tests: Detection of GHRP-2 abuse.
- Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach.
- Determination of the immunostimulatory drug-glucosoaminyl-muramyl-dipeptide-in human plasma using HPLC-MS/MS and its application to a pharmacokinetic study.
- Fully automated dried blood spot sample preparation enables the detection of lower molecular mass peptide and non-peptide doping agents by means of LC-HRMS.
- Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.
- Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas.
- Detection of black market follistatin 344.
- β1-adrenergic receptors mediate plasma acyl-ghrelin elevation and depressive-like behavior induced by chronic psychosocial stress.
- Glycine-modified growth hormone secretagogues identified in seized doping material.
Common Research Stacks
Frequently Asked Questions
Is GHRP-2 or Ipamorelin better?
GHRP-2 produces a stronger GH pulse at equivalent doses, but also elevates cortisol and prolactin. Ipamorelin is more selective and suitable for longer-term protocols where cortisol management matters. GHRP-2 is preferred when maximum GH pulse amplitude is the priority; Ipamorelin when clean hormonal profile matters more.
What dose of GHRP-2 minimises cortisol elevation?
Cortisol elevation is dose-dependent. At 100 mcg, cortisol co-stimulation is minimal and transient. At 200–300 mcg, moderate elevation occurs. Above 300–500 mcg, clinically significant ACTH/cortisol increases are commonly observed. Most research protocols cap GHRP-2 at 100–200 mcg per injection to preserve the GH benefit while limiting cortisol load.
Can GHRP-2 be used as a diagnostic test?
Yes — GHRP-2 combined with GHRH has been studied as a GH deficiency diagnostic tool (the GHRP-2 stimulation test). Research compared it favourably to the insulin tolerance test (ITT) for sensitivity and with fewer hypoglycaemia risks. It is not widely used clinically outside research endocrinology, but its diagnostic utility is well-established in the literature.
How does GHRP-2 affect appetite compared to Ipamorelin?
GHRP-2 stimulates appetite more strongly than Ipamorelin due to partial ghrelin pathway activation. This can be an advantage for researchers studying GH in contexts where anabolism and caloric intake are both goals. For protocols focused on body recomposition or fat loss, the appetite stimulation is typically an unwanted effect that Ipamorelin avoids.
Is GHRP-2 (Pralmorelin) available as a pharmaceutical?
GHRP-2 (branded Pralmorelin in Japan) is approved in Japan for GH deficiency diagnosis. Outside Japan it is used primarily as a research compound. Its pharmaceutical manufacturing in Japan has provided quality-controlled material for clinical studies that inform much of the available safety and pharmacokinetic data.
Key Research References
- Bowers CY et al. (1994). GHRP-2 stimulates GH release in humans. J Clin Endocrinol Metab.
- Popovic V et al. (2002). GHRP-2 test in patients with GH deficiency. Eur J Endocrinol.
Explore more Growth Hormone research compounds
Browse Growth Hormone →